Would treatment decisions about secondary prevention of CVD based on estimated lifetime benefit rather than 10-year risk reduction be cost-effective?
| Autor: | Berkelmans, Gijs F. N., Greving, Jacoba P., van der Graaf, Yolanda, Visseren, Frank L. J., Dorresteijn, Jannick A. N. |
|---|---|
| Zdroj: | Diagnostic & Prognostic Research; 4/16/2020, Vol. 4 Issue 1, p1-13, 13p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink